Key facts
- This page summarizes Sanjay Subramanian's Form 4 filing for Ocugen, Inc. (OCGN).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 05 Jan 2022, 18:33.
Sanjay Subramanian - 03 Jan 2022 Form 4 Insider Report for Ocugen, Inc. (OCGN)
- Reporting relationship
- Chief Financial Officer
- Issuer ticker
- OCGN
- Reported as of
- 03 Jan 2022
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 05 Jan 2022, 18:33:00 UTC
- Prior SEC filing
- 17 Dec 2021
- Next SEC filing
- 22 Mar 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Sanjay Subramanian
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Sanjay Subramanian filed Form 4 for Ocugen, Inc. (OCGN) on 05 Jan 2022.
Change
- Previous filing in this sequence was filed on 17 Dec 2021.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
OCGN
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +125,534
- Change %
- +353%
- Price
- $0.000000
- Shares after
- 161,125
- Date
- 03 Jan 2022
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
OCGN
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +454,007
- Change %
- Price
- $0.000000
- Shares after
- 454,007
- Date
- 03 Jan 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 454,007
- Exercise price
- $4.72
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Reflects the grant of restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Ocugen Inc.'s (the "Company's") common stock. The restricted stock units vest annually in three equal installments commencing on January 3, 2023, subject to continued employment with the Company on the applicable vesting dates. The restricted stock units will be settled on each applicable vesting date in shares of the Company's common stock.
Footnote F2
The option vests annually in equal installments over three years commencing on January 3, 2023, subject to continued employment with the Company on the applicable vesting dates.